epothilone D + trastuzumab

**Epothilone D + trastuzumab** is an investigational combination therapy comprising a small molecule microtubule stabilizer (epothilone D) and a monoclonal antibody targeting HER2/neu (trastuzumab). *Epothilone D* is a macrolide compound that binds to tubulin, stabilizes microtubules, and inhibits cell division resulting in apoptosis, with significant activity against taxane-resistant and multidrug-resistant cancer cells[1][2][4]. *Trastuzumab* is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor, blocking its signaling and mediating antibody-dependent cell-mediated cytotoxicity. The combination is of interest for *HER2-positive breast cancer*, especially where resistance to taxanes and trastuzumab alone is a concern. No direct clinical trial data was found for this precise combination, but related combinations (e.g., epothilone class drugs plus trastuzumab) are conceptually supported in literature.